Now Available! | Check out UMR’s 2024 Annual Economic Report and State Toolkits today
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Rural State Analysis | UMR's 2023 Report Reveals the Exponential Impact of NIH Research Funding in 7 Rural States
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Privacy Policy © 2024 United For Medical Research. All Rights Reserved.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit*, and TaqPath COVID-19 CE-IVD RT-PCR Kit*, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.